A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need ...

A single fecal microbiota transplantation from healthy donors increases the efficacy of immune checkpoint inhibition in both NSCLC and melanoma.

DS-9606 was supposed to be the first antibody-drug conjugate in Daiichi Sankyo’s line of anti-cancer assets to use a modified ...

Study Highlights the Efficacy of PMC in Suppressing Non-Small Cell Lung Cancer Growth SEOUL, SOUTH KOREA, January 23, 2026 /EINPresswire.com/ — A South Korean research team has found that ...

When appropriate, surgery remains the most effective treatment option for non-small cell lung cancer (NSCLC), including for patients with COPD, said Friedberg, professor in the Department of Thoracic ...

The National Comprehensive Cancer Network’s newly updated non-small cell lung cancer guideline adds sevabertinib as a treatment option for some patients with advanced disease, makes datopotamab ...

A deep-learning serial CT biomarker improves survival prediction in immunotherapy-treated NSCLC and outperforms RECIST. Find ...

A 55 year-old struck with 'incurable' stage 4 lung cancer six years ago that spread to his brain has miraculously seen the ...

Breakthrough research presented at the 2026 Society of Thoracic Surgeons Annual Meeting shows that additional lymph node ...

The trial will include patients with pancreatic, colorectal, non-small cell lung, and other cancers that harbor KRAS G12V mutations.

"Reimbursement will be a major milestone for Volition in the commercialization and licensing of Nu.Q® in the human cancer ...

Summit Therapeutics has moved ahead in the race to bring a therapy targeting both VEGF and PD- (L)1 to market, after the FDA started a review of its ivonescimab drug for lung cancer.